News
QuantumBio Inc. Awarded National Institutes of Health Contract to Develop Quantum Mechanics-based Protein/Drug Scoring and Interaction Decomposition Methodologies
March 11, 2008
FOR IMMEDIATE RELEASE: Tuesday, March 11, 2008
CONTACT: Lance M. Westerhoff, 814-235-6908, lance@quantumbioinc.com
State College, PA – March 11, 2008. QuantumBio Inc, headquartered in State College, PA, has been selected to receive a FastTrack Small Business Innovation Research Grant (SBIR) totaling over $865,000 from the National Institutes of Health. The project, under the direction of QuantumBio’s General Manager, Dr. Lance M. Westerhoff, will focus on research and development of novel, quantum mechanics-based methods for the study of protein/drug interactions. These methods, derived from those recently explored in the academic laboratory of Professor Kenneth M. Merz, Jr. of the University of Florida, will ultimately lead to next generation molecular modeling tools used to aid pharmaceutical companies in developing more potent, less expensive drugs and drug-like compounds.
Dr. Westerhoff notes, “We are very excited to have won further support for the development of this technology, which we feel confident will open a new world of possibilities for those interested in the search for new and more potent drug candidates.”
The Phase I SBIR project, which began this past fall, expanded on the early academic development through the implementation of novel interaction determination methods, followed by validation of these methods against a number of enzyme targets of interest to industry. In addition, a joint research and development collaboration with Discovery Machine, Inc, (DMI) based in Williamsport, PA, was undertaken to extend and deploy workflow capture and cognitive modeling capabilities to automate best practices for computational biochemistry. Dr. Todd Griffith, DMI’s President, comments, “DMI is thrilled to see technology originally developed for the Department of Defense providing differentiation in the computational biochemistry market.”
Beginning immediately, the two-year phase II effort will build on this solid foundation and the project will see the technology validated against real-life problems through QuantumBio’s relationships with its pharmaceutical industry partners. In addition to this scientific validation, the support will also be utilized to build a user-friendly, quantum mechanics-based application for drug discovery through integration of QuantumBio’s key products – QM-PWD, QMScore, and QM/SE-COMBINE – with both DMI’s workflow capture, replication, and automation technology; and CHEMIX, QuantumBio’s molecular modeling platform.
About QuantumBio Inc.
QuantumBio Inc. is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies, and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com.
About Discovery Machine, Inc.
Discovery Machine Inc. is a privately-held woman-owned firm, with headquarters in Williamsport, PA, and offices in Raleigh, NC. DMI provides software, methodology, and consulting services that enable knowledge capture and replication. Discovery Machine products and services give “knowledge experts”—strategists, scientists, researchers, and others—the ability to build working process models, simulations, and intelligent agents without the need for scripting languages or complex rule-based systems. Discovery Machine has a successful history in the defense, aerospace, and biomedical research industries including work with the Navy, DARPA, ONR, NASA, Lockheed Martin, Northrop Grumman, and many others. Additional information is available at http://www.discoverymachine.com or by email sales@discoverymachine.com.
CONTACT: Lance M. Westerhoff, 814-235-6908, lance@quantumbioinc.com
State College, PA – March 11, 2008. QuantumBio Inc, headquartered in State College, PA, has been selected to receive a FastTrack Small Business Innovation Research Grant (SBIR) totaling over $865,000 from the National Institutes of Health. The project, under the direction of QuantumBio’s General Manager, Dr. Lance M. Westerhoff, will focus on research and development of novel, quantum mechanics-based methods for the study of protein/drug interactions. These methods, derived from those recently explored in the academic laboratory of Professor Kenneth M. Merz, Jr. of the University of Florida, will ultimately lead to next generation molecular modeling tools used to aid pharmaceutical companies in developing more potent, less expensive drugs and drug-like compounds.
Dr. Westerhoff notes, “We are very excited to have won further support for the development of this technology, which we feel confident will open a new world of possibilities for those interested in the search for new and more potent drug candidates.”
The Phase I SBIR project, which began this past fall, expanded on the early academic development through the implementation of novel interaction determination methods, followed by validation of these methods against a number of enzyme targets of interest to industry. In addition, a joint research and development collaboration with Discovery Machine, Inc, (DMI) based in Williamsport, PA, was undertaken to extend and deploy workflow capture and cognitive modeling capabilities to automate best practices for computational biochemistry. Dr. Todd Griffith, DMI’s President, comments, “DMI is thrilled to see technology originally developed for the Department of Defense providing differentiation in the computational biochemistry market.”
Beginning immediately, the two-year phase II effort will build on this solid foundation and the project will see the technology validated against real-life problems through QuantumBio’s relationships with its pharmaceutical industry partners. In addition to this scientific validation, the support will also be utilized to build a user-friendly, quantum mechanics-based application for drug discovery through integration of QuantumBio’s key products – QM-PWD, QMScore, and QM/SE-COMBINE – with both DMI’s workflow capture, replication, and automation technology; and CHEMIX, QuantumBio’s molecular modeling platform.
About QuantumBio Inc.
QuantumBio Inc. is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies, and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com.
About Discovery Machine, Inc.
Discovery Machine Inc. is a privately-held woman-owned firm, with headquarters in Williamsport, PA, and offices in Raleigh, NC. DMI provides software, methodology, and consulting services that enable knowledge capture and replication. Discovery Machine products and services give “knowledge experts”—strategists, scientists, researchers, and others—the ability to build working process models, simulations, and intelligent agents without the need for scripting languages or complex rule-based systems. Discovery Machine has a successful history in the defense, aerospace, and biomedical research industries including work with the Navy, DARPA, ONR, NASA, Lockheed Martin, Northrop Grumman, and many others. Additional information is available at http://www.discoverymachine.com or by email sales@discoverymachine.com.
QuantumBio Inc. Releases Version 4.5 of its Linear Scaling, Quantum Mechanics Software for Drug Discovery
March 19, 2007
FOR IMMEDIATE RELEASE: Monday, March 19, 2007
CONTACT: Lance M. Westerhoff, 814-235-6908, lance@quantumbioinc.com
State College, PA – March 19, 2007. QuantumBio Inc., headquartered in State College, PA with offices in Gainesville, FL and Lancaster, PA, has released version 4.5 of its DivCon software suite. Based upon technology originally developed at the Pennsylvania State University in the laboratory of Dr. Kenneth Merz Jr., DivCon is the first to target drug discovery teams at pharmaceutical and biotechnology firms with patent pending applications of linear scaling, quantum mechanics methods.
The innovations in version 4.5, built on those of previous versions, allow the user to more easily integrate the tool with his or her computer aided drug discovery workflow through more robust encapsulation of the Company’s patent pending, QMScore technology; better support for standard coordinate file formats; and improved ease-of-use and stability characteristics.
Dr. Lance Westerhoff, General Manager of QuantumBio says: “We think that version 4.5 is the best DivCon version we have released to date with the usability needs of the user in mind. With version 4.5 and its support for standard file formats, better command line options, and significant implementation and stability improvements, the user is able to access the methods much more quickly.”
In support for the new version, QuantumBio’s Support website has also been updated with new documentation. These pages will continue to be updated in the days and weeks to come with additional resources including further examples and publication abstracts pertaining to the technology. Users are also invited to submit their own experiences and publication abstracts to be included on the site. Please visit http://www.quantumbioinc.com/Support/ for more information.
DivCon Version 4.5 (serial) for Linux, Mac OS X, and IRIX will begin shipping this week to all customers with current software license contracts. The parallel (MPI) version, available for Linux and Mac OS X, will ship early next month. New customers are invited to email sales@quantumbioinc.com or visit http://www.quantumbioinc.com/ concerning licensing opportunities.
About QuantumBio:
QuantumBio Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com.
CONTACT: Lance M. Westerhoff, 814-235-6908, lance@quantumbioinc.com
State College, PA – March 19, 2007. QuantumBio Inc., headquartered in State College, PA with offices in Gainesville, FL and Lancaster, PA, has released version 4.5 of its DivCon software suite. Based upon technology originally developed at the Pennsylvania State University in the laboratory of Dr. Kenneth Merz Jr., DivCon is the first to target drug discovery teams at pharmaceutical and biotechnology firms with patent pending applications of linear scaling, quantum mechanics methods.
The innovations in version 4.5, built on those of previous versions, allow the user to more easily integrate the tool with his or her computer aided drug discovery workflow through more robust encapsulation of the Company’s patent pending, QMScore technology; better support for standard coordinate file formats; and improved ease-of-use and stability characteristics.
Dr. Lance Westerhoff, General Manager of QuantumBio says: “We think that version 4.5 is the best DivCon version we have released to date with the usability needs of the user in mind. With version 4.5 and its support for standard file formats, better command line options, and significant implementation and stability improvements, the user is able to access the methods much more quickly.”
In support for the new version, QuantumBio’s Support website has also been updated with new documentation. These pages will continue to be updated in the days and weeks to come with additional resources including further examples and publication abstracts pertaining to the technology. Users are also invited to submit their own experiences and publication abstracts to be included on the site. Please visit http://www.quantumbioinc.com/Support/ for more information.
DivCon Version 4.5 (serial) for Linux, Mac OS X, and IRIX will begin shipping this week to all customers with current software license contracts. The parallel (MPI) version, available for Linux and Mac OS X, will ship early next month. New customers are invited to email sales@quantumbioinc.com or visit http://www.quantumbioinc.com/ concerning licensing opportunities.
About QuantumBio:
QuantumBio Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com.
QuantumBio Inc. Awarded National Institutes of Health Contract to Develop Quantum Mechanics-based NMR Refinement Methodologies
March 12, 2007
FOR IMMEDIATE RELEASE: Monday, March 12, 2007
CONTACT: Lance M. Westerhoff, 814-235-6908, lance@quantumbioinc.com
State College, PA – March 12, 2007. QuantumBio Inc., headquartered in State College, PA with offices in Gainesville, FL and Lancaster, PA, has been selected to receive a FastTrack Small Business Technology Transfer Grant (STTR) grant from the National Institutes of Health valued at approximately $950,000. Titled “Enhancement and Deployment of the Quantum Mechanical NMR Pose Scoring Method”, the project – under the direction of Dr. Kenneth M. Merz Jr., Professor of Chemistry at the University of Florida and Chief Scientific Officer of QuantumBio Inc. and Dr. Lance M. Westerhoff, General Manager of QuantumBio Inc. − will focus on transitioning the novel, quantum mechanically based NMR refinement technologies recently developed in the Merz laboratory to QuantumBio’s product line.
The Phase I STTR project, which began this past fall, expanded on the early, academic development of the methodology and added technologies more applicable to the pharmaceutical and biotechnology industries. Successful completion of the Phase I research provided a foundation for a two-year research and development effort. Phase II begins immediately, and the results of the project will see the technology validated against real-life problems through QuantumBio’s relationships with its industry partners.
By the conclusion of this research phase, QuantumBio will have further expanded on the development of a user-friendly application for drug discovery through the stronger integration of quantum mechanics-based NMR refinement technologies and QuantumBio’s molecular modeling platform, CHEMIX. Ultimately, the supported projects will lead to next generation molecular modeling tools that will aide pharmaceutical and biotechnology companies in developing more potent, less expensive drugs and drug-like compounds.
About QuantumBio
QuantumBio Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com.
Note: The project discussed in this press release is sponsored by the National Institutes of Health. The content of this press release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
CONTACT: Lance M. Westerhoff, 814-235-6908, lance@quantumbioinc.com
State College, PA – March 12, 2007. QuantumBio Inc., headquartered in State College, PA with offices in Gainesville, FL and Lancaster, PA, has been selected to receive a FastTrack Small Business Technology Transfer Grant (STTR) grant from the National Institutes of Health valued at approximately $950,000. Titled “Enhancement and Deployment of the Quantum Mechanical NMR Pose Scoring Method”, the project – under the direction of Dr. Kenneth M. Merz Jr., Professor of Chemistry at the University of Florida and Chief Scientific Officer of QuantumBio Inc. and Dr. Lance M. Westerhoff, General Manager of QuantumBio Inc. − will focus on transitioning the novel, quantum mechanically based NMR refinement technologies recently developed in the Merz laboratory to QuantumBio’s product line.
The Phase I STTR project, which began this past fall, expanded on the early, academic development of the methodology and added technologies more applicable to the pharmaceutical and biotechnology industries. Successful completion of the Phase I research provided a foundation for a two-year research and development effort. Phase II begins immediately, and the results of the project will see the technology validated against real-life problems through QuantumBio’s relationships with its industry partners.
By the conclusion of this research phase, QuantumBio will have further expanded on the development of a user-friendly application for drug discovery through the stronger integration of quantum mechanics-based NMR refinement technologies and QuantumBio’s molecular modeling platform, CHEMIX. Ultimately, the supported projects will lead to next generation molecular modeling tools that will aide pharmaceutical and biotechnology companies in developing more potent, less expensive drugs and drug-like compounds.
About QuantumBio
QuantumBio Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com.
Note: The project discussed in this press release is sponsored by the National Institutes of Health. The content of this press release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
QuantumBio Inc. Awarded Department of Defense Grant to Develop Tools That Will Counter Biothreats: Funding Will Facilitate Adaptation of Technology Originally Designed for Drug Discovery
July 05, 2005
State College, PA – July 5, 2005. QuantumBio
Inc., headquartered in Harrisburg, PA with offices in
State College, PA and San Diego, CA, has been
selected to receive a Phase I Small Business
Innovation Research (SBIR) grant, valued at $63,353,
from the U.S. Army Research Office. Titled “In
Silico Screening for Biothreat
Countermeasures”, the project – under the
direction of Principle Investigator Lance Westerhoff
− will apply QuantumBio’s novel quantum
mechanics-based technology to the study of
next-generation tools to counter bioterrorism.
Originally developed for the pharmaceutical industry, the company’s in silico (computer aided) drug discovery tools are ideally suited to counter-bioterrorism efforts, where, in the case of a bioterrorist attack, the Department of Defense will require fast and accurate prediction methods to quickly determine viable treatment options.
At a fundamental level, these technologies address many of the same needs as those of the drug discovery industry. QMScore – QuantumBio’s propriety scoring algorithm – along with its various support products − uses the power and precision of quantum mechanics to solve the problems of the defense and pharmaceutical industries alike. In the proposed research, to be conducted in collaboration with a number of industry partners, further validation will be performed on QMScore.
At the conclusion of this research phase, QuantumBio will further expand on the development of a user-friendly application for drug discovery and counter-bioterrorism through the stronger integration of QMScore and QuantumBio’s molecular modeling platform, CHEMIX, with a knowledge management and intelligent workflow platform. At the same time, further research into the various applications of this novel technology will be performed. The ultimate goal of this project is the development of an intelligent and adaptive molecular modeling system for quantum mechanics-based drug discovery and counter-bioterrorism.
About QuantumBio
QuantumBio, Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com or by calling 814-235-6908.
Note: The project or effort depicted is sponsored by the U.S. Army Research Office, and that the content of the this press release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
Originally developed for the pharmaceutical industry, the company’s in silico (computer aided) drug discovery tools are ideally suited to counter-bioterrorism efforts, where, in the case of a bioterrorist attack, the Department of Defense will require fast and accurate prediction methods to quickly determine viable treatment options.
At a fundamental level, these technologies address many of the same needs as those of the drug discovery industry. QMScore – QuantumBio’s propriety scoring algorithm – along with its various support products − uses the power and precision of quantum mechanics to solve the problems of the defense and pharmaceutical industries alike. In the proposed research, to be conducted in collaboration with a number of industry partners, further validation will be performed on QMScore.
At the conclusion of this research phase, QuantumBio will further expand on the development of a user-friendly application for drug discovery and counter-bioterrorism through the stronger integration of QMScore and QuantumBio’s molecular modeling platform, CHEMIX, with a knowledge management and intelligent workflow platform. At the same time, further research into the various applications of this novel technology will be performed. The ultimate goal of this project is the development of an intelligent and adaptive molecular modeling system for quantum mechanics-based drug discovery and counter-bioterrorism.
About QuantumBio
QuantumBio, Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com or by calling 814-235-6908.
Note: The project or effort depicted is sponsored by the U.S. Army Research Office, and that the content of the this press release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
Life Science Greenhouse of Central PA (LSGPA) invests in QuantumBio for accelerating drug discovery efforts using unique molecular modeling tools
June 23, 2003
State College, PA -- June 23, 2003 -- The Life
Sciences Greenhouse of Central Pennsylvania (LSGPA)
has invested close to $1 million in two promising
biotechnology startup companies headquartered in
State College, PA. NanoHorizons, Inc., a developer
and producer of state-of-the-art nanotechnology
products and processes, receive $500,000. QuantumBio,
Inc., a software company that seeks to accelerate
drug discovery efforts using unique molecular
modeling tools, received $425,000. These represent
the first of LSGPA's pre-seed stage investments,
which are expected to total roughly $10 million over
five years. Additionally, the companies received
matching fund commitments exceeding $4 million.
From left to right: Mel Billingsley, President &
CEO of the Life Sciences Greenhouse of Central PA;
Dennis Yablonsky, Secretary PA Department of
Community and Economic Development; Lance Westerhoff,
Chief Software Engineer of QuantumBio, Inc.; Kenneth
Merz, CEO of QuantumBio; Walter Greenblatt, CFO of
QunatumBio; and Kevin Harter, Senior V.P. Business
Development of the Life Sciences Greenhouse of
Central PA
About QuantumBio, Inc.
QuantumBio's software suite of quantum
mechanically-based molecular modeling tools and
unique database of protein structures critical to
drug discovery are based on technology developed
between 1995 and the present at Penn State University
(PSU) in the labs of Dr. Kenneth Merz, an
international leader in the field of computational
chemistry for drug discovery. These proprietary tools
will enable scientists engaged in drug discovery to
leverage the precision of quantum mechanical
approaches to model interactions between proteins and
small molecules far better than the classical
mechanics-based software models currently available
on the market. In addition, the company is expected
to benefit from an expanding list of technology
emerging from PSU in the form of provisional patents
and invention disclosures.
Pennsylvania's Ben Franklin Technology PArtners (Central Region) awards a phase 1 investment in QuantumBio.
June 18, 2003
State College, PA — June 18, 2003 —
QuantumBio Inc., pioneering a next generation of
Computer-Assisted Molecular Modeling (CAMM) and
Computer-Assisted Drug Design (CADD) tools was
awarded a technology grant from Ben Franklin
Technology PArtners of Pennsylvania.
Ben Franklin Technology PArtners (BFTP) is a Commonwealth of Pennsylvania program established to foster innovation and economic growth. Established in 1983, BFTP provides capital to support the development of promising products and technologies by Pennsylvania-based companies.
QuantumBio received the BFTP grant to support the expanded development of proprietary technology developed by QuantumBio to model the complex quantum mechanically-based molecular modeling tools and unique database of protein structures critical to drug discovery. These proprietary tools will enable scientists engaged in drug discovery to leverage the precision of quantum mechanical approaches to model interactions between proteins and small molecules far better than the classical mechanics-based software models currently available on the market.
About Ben Franklin Technology Partners
For more than two decades, Ben Franklin Technology Partners, an international model for innovation in technology-based economic development, has worked to diversify and strengthen Pennsylvania’s economy by focusing on entrepreneurial development and technological innovation. BFTP delivers resources for technology-driven enterprises in sectors such as information technology, life sciences, communications, advanced manufacturing, advanced materials and environmental technology.
About QuantumBio, Inc.
QuantumBio's software suite of quantum mechanically-based molecular modeling tools and unique database of protein structures critical to drug discovery are based on technology developed between 1995 and the present at Penn State University (PSU) in the labs of Dr. Kenneth Merz, an international leader in the field of computational chemistry for drug discovery. These proprietary tools will enable scientists engaged in drug discovery to leverage the precision of quantum mechanical approaches to model interactions between proteins and small molecules far better than the classical mechanics-based software models currently available on the market. In addition, the company is expected to benefit from an expanding list of technology emerging from PSU in the form of provisional patents and invention disclosures.
Ben Franklin Technology PArtners (BFTP) is a Commonwealth of Pennsylvania program established to foster innovation and economic growth. Established in 1983, BFTP provides capital to support the development of promising products and technologies by Pennsylvania-based companies.
QuantumBio received the BFTP grant to support the expanded development of proprietary technology developed by QuantumBio to model the complex quantum mechanically-based molecular modeling tools and unique database of protein structures critical to drug discovery. These proprietary tools will enable scientists engaged in drug discovery to leverage the precision of quantum mechanical approaches to model interactions between proteins and small molecules far better than the classical mechanics-based software models currently available on the market.
About Ben Franklin Technology Partners
For more than two decades, Ben Franklin Technology Partners, an international model for innovation in technology-based economic development, has worked to diversify and strengthen Pennsylvania’s economy by focusing on entrepreneurial development and technological innovation. BFTP delivers resources for technology-driven enterprises in sectors such as information technology, life sciences, communications, advanced manufacturing, advanced materials and environmental technology.
About QuantumBio, Inc.
QuantumBio's software suite of quantum mechanically-based molecular modeling tools and unique database of protein structures critical to drug discovery are based on technology developed between 1995 and the present at Penn State University (PSU) in the labs of Dr. Kenneth Merz, an international leader in the field of computational chemistry for drug discovery. These proprietary tools will enable scientists engaged in drug discovery to leverage the precision of quantum mechanical approaches to model interactions between proteins and small molecules far better than the classical mechanics-based software models currently available on the market. In addition, the company is expected to benefit from an expanding list of technology emerging from PSU in the form of provisional patents and invention disclosures.